Background: Clinical practice guidelines for the management of cholangiocarcinoma (CCA)/biliary tract cancer recommend genomic profiling to guide treatment decisions. Variable access to such profiling across Italy means many oncologists are unfamiliar with when and how to conduct genetic testing and prescribe targeted treatments. Methods: A Scientific Board of Italian oncologists who treat CCA (the authors) developed recommendations, based on recent clinical evidence, for using molecular testing in diagnosing, assessing, and treating CCA in Italy. The Delphi process was used to reach consensus on these recommendations among 38 Italian oncologists. Consensus was considered to be met if ≥ 66.7 % of the panel agreed or strongly agreed with each statement. Findings: Consensus was reached on 28 statements across four themes: (1) epidemiology and risk factors; (2) diagnosis, including molecular diagnosis; (3) treatment selection; and (4) treatment safety. Interpretation: These recommendations should aid Italian clinicians in selecting appropriate treatment options for their patients.

Diagnosis and treatment of cholangiocarcinoma in Italy: A Delphi consensus statement

Mattioli, Stefano
Membro del Collaboration Group
;
2023

Abstract

Background: Clinical practice guidelines for the management of cholangiocarcinoma (CCA)/biliary tract cancer recommend genomic profiling to guide treatment decisions. Variable access to such profiling across Italy means many oncologists are unfamiliar with when and how to conduct genetic testing and prescribe targeted treatments. Methods: A Scientific Board of Italian oncologists who treat CCA (the authors) developed recommendations, based on recent clinical evidence, for using molecular testing in diagnosing, assessing, and treating CCA in Italy. The Delphi process was used to reach consensus on these recommendations among 38 Italian oncologists. Consensus was considered to be met if ≥ 66.7 % of the panel agreed or strongly agreed with each statement. Findings: Consensus was reached on 28 statements across four themes: (1) epidemiology and risk factors; (2) diagnosis, including molecular diagnosis; (3) treatment selection; and (4) treatment safety. Interpretation: These recommendations should aid Italian clinicians in selecting appropriate treatment options for their patients.
2023
Rimassa, Lorenza; Brandi, Giovanni; Niger, Monica; Normanno, Nicola; Melisi, ; Davide (and Working group, Casadei-Gardini; Andrea, ; Daniele, Bruno; Garufi, Carlo; Solda, Caterina; Vivaldi, Caterina; Santini, Daniele; Martinelli, Erika; Giuliani, Francesco; Leone, Francesco; Cardellino, Giovanni; Nasti, Guglielmo; Rapposelli, Ilario; Fornaro, Lorenzo; Silvestro, Lucrezia; Muratori, Luigi; Galli, Paolo; Lonardi, Sara; Curti, Stefania; Mattioli, Stefano; Pressiani, Tiziana; Burgio, Valentina; Cardinale, Vincenzo; Damato, Angela; Stagno, Annamaria; Diana, Anna; Santaniello, Antonio; Cardone, Claudia; Giommoni, Elisa; Lo Prinzi, Federica; Nichetti, Federico; Masi, Gianluca; Arcangeli, Giuseppina; Salati, Massimiliano; Verrico, Monica; Federico, Piera; Ziranu, Pina; Corallo, Salvatore; Noventa, Silvia)
File in questo prodotto:
File Dimensione Formato  
Delphi consensus Crit rev oncol hematol 2023.pdf

solo gestori archivio

Descrizione: versione editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.99 MB
Formato Adobe PDF
1.99 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2535684
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact